1bnd Citations

Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer.

Biochemistry 34 4139-46 (1995)
Cited: 68 times
EuropePMC logo PMID: 7703225


The development and sustenance of specific neuronal populations in the peripheral and central nervous systems are controlled through the binding of neurotrophic factors to high-affinity cell surface receptors. The neurotrophins (nerve growth factor, NGF; brain-derived neurotrophic factor, BDNF; neurotrophin 3, NT3; and neurotrophin 4, NT4) are dimeric molecules which share approximately 50% sequence identity. The crystal structure of the murine NGF homodimer [McDonald et al. (1991) Nature 354, 411-414] indicated that the dimer interface corresponds to regions of high sequence conservation throughout the neurotrophin family. This potential compatibility was duly exploited for the production in vitro of noncovalent heterodimers between the different neurotrophins [Radziejewski, C., & Robinson, R.C. (1993) Biochemistry 32, 13350-13356; Jungbluth et al. (1994) Eur. J. Biochem. 221, 677-685]. Here, we report the X-ray structure at 2.3 A resolution of one such heterodimer, between human BDNF, and human NT3. The NGF, BDNF, and NT3 protomers share the same topology and are structurally equivalent in regions which contribute to the dimer interface in line with the propensity of the neurotrophins to form heterodimers. Analysis of the structure of regions of the BDNF/NT3 heterodimer involved in receptor specificity led us to conclude that heterodimer binding to p75 involves distant binding sites separately located on each protomer of the heterodimer. In contrast, heterodimer interactions with the trk receptors probably utilize hybrid binding sites comprised of residues contributed by both protomers in the heterodimer. The existence of such hybrid binding sites for the trk receptor provides an explanation for the lower activity of the BDNF/NT3 heterodimer in comparison to the homodimers.(ABSTRACT TRUNCATED AT 250 WORDS)

Reviews - 1bnd mentioned but not cited (2)

  1. HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads. Borgmann K, Ghorpade A. Front Microbiol 6 1143 (2015)
  2. Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness. Khalin I, Alyautdin R, Kocherga G, Bakar MA. Int J Nanomedicine 10 3245-3267 (2015)

Articles - 1bnd mentioned but not cited (10)

  1. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. Cazorla M, Prémont J, Mann A, Girard N, Kellendonk C, Rognan D. J. Clin. Invest. 121 1846-1857 (2011)
  2. From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Géral C, Angelova A, Lesieur S. Pharmaceutics 5 127-167 (2013)
  3. Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A, Prémont J. PLoS ONE 5 e9777 (2010)
  4. Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor. Fletcher JM, Morton CJ, Zwar RA, Murray SS, O'Leary PD, Hughes RA. J. Biol. Chem. 283 33375-33383 (2008)
  5. Agonistic effect of polyunsaturated fatty acids (PUFAs) and its metabolites on brain-derived neurotrophic factor (BDNF) through molecular docking simulation. Vetrivel U, Ravichandran SB, Kuppan K, Mohanlal J, Das UN, Narayanasamy A. Lipids Health Dis 11 109 (2012)
  6. BDNF Binds Its Pro-Peptide with High Affinity and the Common Val66Met Polymorphism Attenuates the Interaction. Uegaki K, Kumanogoh H, Mizui T, Hirokawa T, Ishikawa Y, Kojima M. Int J Mol Sci 18 (2017)
  7. A relation between the principal axes of inertia and ligand binding. Foote J, Raman A. Proc. Natl. Acad. Sci. U.S.A. 97 978-983 (2000)
  8. CARDIO-PRED: an in silico tool for predicting cardiovascular-disorder associated proteins. Jain P, Thukral N, Gahlot LK, Hasija Y. Syst Synth Biol 9 55-66 (2015)
  9. Comparative insights using the molecular homology model of BDNF (Brain derived neurotrophic factor) of Varanus komodoensis and the known NGF (Nerve growth factor) structure of Naja atra. Verma A, Sharma DK, Sarma R, Chetia H, Saikia J. Bioinformation 9 755-758 (2013)
  10. In silico analysis of the V66M variant of human BDNF in psychiatric disorders: An approach to precision medicine. De Oliveira CCS, Pereira GRC, De Alcantara JYS, Antunes D, Caffarena ER, De Mesquita JF. PLoS ONE 14 e0215508 (2019)

Reviews citing this publication (18)

  1. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. Pardridge WM. BioDrugs 31 503-519 (2017)
  2. Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy. Pramanik S, Sulistio YA, Heese K. Mol. Neurobiol. 54 7401-7459 (2017)
  3. Neurotrophins and Proneurotrophins: Focus on Synaptic Activity and Plasticity in the Brain. Gibon J, Barker PA. Neuroscientist 23 587-604 (2017)
  4. Brain-derived neurotrophic factor in the airways. Prakash YS, Martin RJ. Pharmacol. Ther. 143 74-86 (2014)
  5. Neurotrophins: Role in adverse pregnancy outcome. Dhobale M. Int. J. Dev. Neurosci. 37 8-14 (2014)
  6. Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Lühder F, Gold R, Flügel A, Linker RA. Arch. Immunol. Ther. Exp. (Warsz.) 61 95-105 (2013)
  7. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Eibl JK, Strasser BC, Ross GM. Neurochem. Int. 61 1266-1275 (2012)
  8. Neurotrophins in lung health and disease. Prakash Y, Thompson MA, Meuchel L, Pabelick CM, Mantilla CB, Zaidi S, Martin RJ. Expert Rev Respir Med 4 395-411 (2010)
  9. Cardiovascular actions of neurotrophins. Caporali A, Emanueli C. Physiol. Rev. 89 279-308 (2009)
  10. Neurotrophin-regulated signalling pathways. Reichardt LF. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 361 1545-1564 (2006)
  11. Neurotrophins and neurodegeneration. Dawbarn D, Allen SJ. Neuropathol. Appl. Neurobiol. 29 211-230 (2003)
  12. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Murer MG, Yan Q, Raisman-Vozari R. Prog. Neurobiol. 63 71-124 (2001)
  13. Nerve growth factor signaling, neuroprotection, and neural repair. Sofroniew MV, Howe CL, Mobley WC. Annu. Rev. Neurosci. 24 1217-1281 (2001)
  14. Neurotrophins: roles in neuronal development and function. Huang EJ, Reichardt LF. Annu. Rev. Neurosci. 24 677-736 (2001)
  15. Emerging themes in structural biology of neurotrophic factors. Ibáñez CF. Trends Neurosci. 21 438-444 (1998)
  16. Getting knotted: a model for the structure and activation of Spätzle. Mizuguchi K, Parker JS, Blundell TL, Gay NJ. Trends Biochem. Sci. 23 239-242 (1998)
  17. Growth factor receptors: structure, mechanism, and drug discovery. McInnes C, Sykes BD. Biopolymers 43 339-366 (1997)
  18. Neurotrophic factors and the development of drugs to promote motoneuron survival. Hughes RA, O'Leary PD. Clin. Exp. Pharmacol. Physiol. 23 965-969 (1996)

Articles citing this publication (38)

  1. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM. J. Clin. Invest. 120 1774-1785 (2010)
  2. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD. J. Biol. Chem. 284 10890-10900 (2009)
  3. Sorting and activity-dependent secretion of BDNF require interaction of a specific motif with the sorting receptor carboxypeptidase e. Lou H, Kim SK, Zaitsev E, Snell CR, Lu B, Loh YP. Neuron 45 245-255 (2005)
  4. Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor. Farhadi HF, Mowla SJ, Petrecca K, Morris SJ, Seidah NG, Murphy RA. J. Neurosci. 20 4059-4068 (2000)
  5. Multiple functions of precursor BDNF to CNS neurons: negative regulation of neurite growth, spine formation and cell survival. Koshimizu H, Kiyosue K, Hara T, Hazama S, Suzuki S, Uegaki K, Nagappan G, Zaitsev E, Hirokawa T, Tatsu Y, Ogura A, Lu B, Kojima M. Mol Brain 2 27 (2009)
  6. Neurotrophin-7: a novel member of the neurotrophin family from the zebrafish. Nilsson AS, Fainzilber M, Falck P, Ibáñez CF. FEBS Lett. 424 285-290 (1998)
  7. Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins. Ross GM, Shamovsky IL, Lawrance G, Solc M, Dostaler SM, Jimmo SL, Weaver DF, Riopelle RJ. Nat. Med. 3 872-878 (1997)
  8. The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/neurotrophin 4 heterodimer reveal a common Trk-binding site. Robinson RC, Radziejewski C, Spraggon G, Greenwald J, Kostura MR, Burtnick LD, Stuart DI, Choe S, Jones EY. Protein Sci. 8 2589-2597 (1999)
  9. Brain-derived neurotrophic factor and TrkB tyrosine kinase receptor gene expression in zebrafish embryo and larva. Lum T, Huynh G, Heinrich G. Int. J. Dev. Neurosci. 19 569-587 (2001)
  10. Identification and selective destruction of shared epitopes in human chorionic gonadotropin beta subunit. Jackson AM, Klonisch T, Lapthorn AJ, Berger P, Isaacs NW, Delves PJ, Lund T, Roitt IM. J. Reprod. Immunol. 31 21-36 (1996)
  11. Phylogenesis of brain-derived neurotrophic factor (BDNF) in vertebrates. Tettamanti G, Cattaneo AG, Gornati R, de Eguileor M, Bernardini G, Binelli G. Gene 450 85-93 (2010)
  12. Activation of pro-BDNF by the pericellular serine protease plasmin. Gray K, Ellis V. FEBS Lett. 582 907-910 (2008)
  13. The interaction of neurotrophins with the p75NTR common neurotrophin receptor: a comprehensive molecular modeling study. Shamovsky IL, Ross GM, Riopelle RJ, Weaver DF. Protein Sci. 8 2223-2233 (1999)
  14. PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. Soderquist RG, Milligan ED, Sloane EM, Harrison JA, Douvas KK, Potter JM, Hughes TS, Chavez RA, Johnson K, Watkins LR, Mahoney MJ. J Biomed Mater Res A 91 719-729 (2009)
  15. Directed evolution of brain-derived neurotrophic factor for improved folding and expression in Saccharomyces cerevisiae. Burns ML, Malott TM, Metcalf KJ, Hackel BJ, Chan JR, Shusta EV. Appl. Environ. Microbiol. 80 5732-5742 (2014)
  16. Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor. Eibl JK, Chapelsky SA, Ross GM. J Pharmacol Exp Ther 332 446-454 (2010)
  17. Two restricted sites on the surface of the nerve growth factor molecule independently determine specific TrkA receptor binding and activation. Kullander K, Kaplan D, Ebendal T. J. Biol. Chem. 272 9300-9307 (1997)
  18. Highly constrained multiple-copy refinement of protein crystal structures. Pellegrini M, Grønbech-Jensen N, Kelly JA, Pfluegl GM, Yeates TO. Proteins 29 426-432 (1997)
  19. Insights into the interaction of sortilin with proneurotrophins: a computational approach. Paiardini A, Caputo V. Neuropeptides 42 205-214 (2008)
  20. bFGF induces differentiation and death of olfactory neuroblastoma cells. Nibu K, Li G, Kaga K, Rothstein JL. Biochem. Biophys. Res. Commun. 279 172-180 (2000)
  21. Characterization of the recombinant extracellular domain of the neurotrophin receptor TrkA and its interaction with nerve growth factor (NGF). Woo SB, Whalen C, Neet KE. Protein Sci. 7 1006-1016 (1998)
  22. RhNGF slow unfolding is not due to proline isomerization: possibility of a cystine knot loop-threading mechanism. De Young LR, Burton LE, Liu J, Powell MF, Schmelzer CH, Skelton NJ. Protein Sci. 5 1554-1566 (1996)
  23. Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia. Wysokiński A. Nord J Psychiatry 70 267-271 (2016)
  24. Copper, BDNF and Its N-terminal domain: inorganic features and biological perspectives. Travaglia A, La Mendola D, Magrì A, Nicoletti VG, Pietropaolo A, Rizzarelli E. Chemistry 18 15618-15631 (2012)
  25. Sex Steroids Influence Brain-Derived Neurotropic Factor Secretion From Human Airway Smooth Muscle Cells. Wang SY, Freeman MR, Sathish V, Thompson MA, Pabelick CM, Prakash YS. J. Cell. Physiol. 231 1586-1592 (2016)
  26. Changes in protein conformation and dynamics upon complex formation of brain-derived neurotrophic factor and its receptor: investigation by isotope-edited Fourier transform IR spectroscopy. Li T, Talvenheimo J, Zeni L, Rosenfeld R, Stearns G, Arakawa T. Biopolymers 67 10-19 (2002)
  27. Specificity of neurotrophin-3 determined by loss-of-function mutagenesis. Kullander K, Kylberg A, Ebendal T. J. Neurosci. Res. 50 496-503 (1997)
  28. Structural and functional insights into lipid-bound nerve growth factors. Tong Q, Wang F, Zhou HZ, Sun HL, Song H, Shu YY, Gong Y, Zhang WT, Cai TX, Yang FQ, Tang J, Jiang T. FASEB J. 26 3811-3821 (2012)
  29. Three-tier regulation of cell number plasticity by neurotrophins and Tolls in Drosophila. Foldi I, Anthoney N, Harrison N, Gangloff M, Verstak B, Nallasivan MP, AlAhmed S, Zhu B, Phizacklea M, Losada-Perez M, Moreira M, Gay NJ, Hidalgo A. J. Cell Biol. 216 1421-1438 (2017)
  30. Metal-catalyzed oxidation of brain-derived neurotrophic factor (BDNF): analytical challenges for the identification of modified sites. Jensen JL, Kolvenbach C, Roy S, Schöneich C. Pharm. Res. 17 190-196 (2000)
  31. A common mechanism for recombinant human NGF, BDNF, NT-3, and murine NGF slow unfolding. De Young LR, Schmelzer CH, Burton LE. Protein Sci. 8 2513-2518 (1999)
  32. Nanoformulation of Brain-Derived Neurotrophic Factor with Target Receptor-Triggered-Release in the Central Nervous System. Jiang Y, Fay JM, Poon CD, Vinod N, Zhao Y, Bullock K, Qin S, Manickam DS, Yi X, Banks WA, Kabanov AV. Adv Funct Mater 28 (2018)
  33. Weak conservation of structural features in the interfaces of homologous transient protein-protein complexes. Sudha G, Singh P, Swapna LS, Srinivasan N. Protein Sci. 24 1856-1873 (2015)
  34. Crystals of the neurotrophins. Robinson RC, Radziejewski C, Stuart DI, Jones EY. Protein Sci. 5 973-977 (1996)
  35. Drug-binding cavities in long-lived biologics: cause for concern but also potential benefit. Panayotatos N. J Clin Pharmacol 48 1208-1211 (2008)
  36. N-Glycosylation is required for secretion of the precursor to brain-derived neurotrophic factor (proBDNF) carrying sulfated LacdiNAc structures. Benicky J, Sanda M, Brnakova Kennedy Z, Goldman R. J. Biol. Chem. 294 16816-16830 (2019)
  37. Novel design of (PEG-ylated)PAMAM-based nanoparticles for sustained delivery of BDNF to neurotoxin-injured differentiated neuroblastoma cells. Dąbkowska M, Łuczkowska K, Rogińska D, Sobuś A, Wasilewska M, Ulańczyk Z, Machaliński B. J Nanobiotechnology 18 120 (2020)
  38. TLR4 Stimulation Promotes Human AVIC Fibrogenic Activity through Upregulation of Neurotrophin 3 Production. Yao Q, The E, Ao L, Zhai Y, Osterholt MK, Fullerton DA, Meng X. Int J Mol Sci 21 (2020)

Related citations provided by authors (1)

  1. Heterodimers of the neurotrophic factors: formation, isolation, and differential stability.. Radziejewski C, Robinson RC Biochemistry 32 13350-6 (1993)